Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?

Atrial fibrillation is a risk factor for dementia and anticoagulant agents have been proven to decrease it. This work aims to find differences in the risk of dementia between patients treated with traditional choice warfarin vs. different direct anticoagulants.

Fibrilación auricular y demencia ¿Qué anticoagulante tiene el menor riesgo?

Between 2014 and 2017, this study enrolled 72,846 patients >40 years with nonvalvular atrial fibrillation who were anticoagulant agent naïve. The primary endpoint was the incidence of dementia.

Of all patients, 25,498 were treated with warfarin, while the remaining 46,898 received direct anticoagulants (17,193 for rivaroxaban, 9882 for dabigatran, 11,992 for apixaban, and 7831 for endoxaban).

After a follow-up period of 1.3 ± 1.1 years, a crude incidence of 4.87/100 patient-years (1.2/100 patient-years for vascular dementia and 3.3/100 patient-years for Alzheimer’s dementia) was observed.

Warfarin and the new anticoagulants had a comparable risk for both global dementia and vascular dementia or Alzheimer’s disease.

In a subgroup analysis, direct inhibitors showed lower risk of dementia than warfarin in patients aged 65 to 74 years (hazard ratio [HR]: 0.815. 95% confidence interval [CI]:  0.7 to 0.9), and in patients with prior stroke (HR: 0.891; 95% CI: 0.8 to 0.9).


Read also: AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?


When comparing direct inhibitors individually to warfarin, endoxaban was the winner.

Conclusion

In this large cohort of patients with atrial fibrillation, direct inhibitors accounted for a similar risk level for dementia compared with classic treatment warfarin. The new drugs were superior in the subgroup of patients aged 65 to 74 and in patients with prior stroke.

Original Title: Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation.

Reference: So-Ryoung Lee et al. Stroke. 2021 Nov;52(11):3459-3468. doi: 10.1161/STROKEAHA.120.033338.  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...